Koāte-DVI is indicated for the treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor, factor VIII.
Learn More
Safety Standards
Kedrion Biopharma continuously seeks the highest standards in quality, safety, and processes.
Koate-DVI is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.
Learn More
Introducing the Koāte-DVI TRY-IT Program
The Koāte-DVI TRY-IT Program offers qualifying patients up to 2 weeks of free Koāte-DVI.
Learn More

Koāte®-DVI [Antihemophilic Factor (Human)]

Koāte-DVI is a human plasma-derived factor VIII replacement therapy that is indicated to treat patients with hemophilia A for over 10 years. Koāte-DVI is proven to rapidly increase levels of factor VIII and to stop bleeding episodes.1 Koāte-DVI has a low risk for side effects, is manufactured with dedicated steps to inactivate or remove viruses, and is available in a range of dosing strengths for use at home or at a doctor’s office.

Reference: 1. Powell JS, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson AR, Hurst D. Safety and efficacy of solvent/detergent- treated antihaemophilic factor with an added 80 degrees C terminal dry heat treatment in patients with haemophilia A. Haemophilia. 2000;6(3):140-9.